Eli Lilly and Company (NYSE:LLY) Shares Bought by GAM Holding AG

GAM Holding AG lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,394 shares of the company's stock after acquiring an additional 1,904 shares during the period. Eli Lilly and Company makes up 2.3% of GAM Holding AG's portfolio, making the stock its 9th biggest position. GAM Holding AG's holdings in Eli Lilly and Company were worth $29,232,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. FPC Investment Advisory Inc. boosted its position in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares during the last quarter. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter valued at about $48,000. Highline Wealth Partners LLC boosted its stake in Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after acquiring an additional 24 shares during the last quarter. Finally, Capital A Wealth Management LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at $63,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on LLY. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Guggenheim reiterated a "buy" rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,011.79.

Eli Lilly and Company Trading Down 2.8%

Shares of NYSE:LLY opened at $763.43 on Friday. The company has a market cap of $723.53 billion, a PE ratio of 62.12, a P/E/G ratio of 1.11 and a beta of 0.40. The company's 50-day moving average price is $780.48 and its 200 day moving average price is $800.93. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.79%. Eli Lilly and Company's payout ratio is 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.